Cardiopulmonary exercise testing predicts prognosis in amyloid cardiomyopathy: a systematic review and meta-analysis.
Amyloidosis
CPET
Heart failure
Mortality
VE/VCO slope
VO2 peak
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
17
04
2023
received:
24
11
2022
accepted:
08
05
2023
medline:
31
7
2023
pubmed:
2
6
2023
entrez:
2
6
2023
Statut:
ppublish
Résumé
The clinical value of cardiopulmonary exercise testing (CPET) in cardiac amyloidosis (CA) is uncertain. Due to the growing prevalence of the disease and the current availability of disease-modifying drugs, prognostic stratification is becoming fundamental to optimizing the cost-effectiveness of treatment, patient phenotyping, follow-up, and management. Peak VO We performed a systematic review and searched for clinical studies performing CPET for prognostication in patients with transthyretin-CA and light-chain-CA. Studies reporting hazard ratio (HR) for mortality and peak VO CPET is a valuable tool for prognostic stratification in CA, identifying patients at increased risk of death. Large prospective clinical trials are needed to confirm this exploratory finding.
Sections du résumé
BACKGROUND
The clinical value of cardiopulmonary exercise testing (CPET) in cardiac amyloidosis (CA) is uncertain. Due to the growing prevalence of the disease and the current availability of disease-modifying drugs, prognostic stratification is becoming fundamental to optimizing the cost-effectiveness of treatment, patient phenotyping, follow-up, and management. Peak VO
METHODS AND RESULTS
We performed a systematic review and searched for clinical studies performing CPET for prognostication in patients with transthyretin-CA and light-chain-CA. Studies reporting hazard ratio (HR) for mortality and peak VO
CONCLUSIONS
CPET is a valuable tool for prognostic stratification in CA, identifying patients at increased risk of death. Large prospective clinical trials are needed to confirm this exploratory finding.
Identifiants
pubmed: 37264762
doi: 10.1002/ehf2.14406
pmc: PMC10375073
doi:
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2740-2744Informations de copyright
© 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
ESC Heart Fail. 2023 Aug;10(4):2740-2744
pubmed: 37264762
Eur J Heart Fail. 2021 Feb;23(2):231-239
pubmed: 33006180
Front Cardiovasc Med. 2022 Jun 06;9:898033
pubmed: 35734274
Intern Emerg Med. 2023 Mar;18(2):585-593
pubmed: 36396841
Am J Cardiol. 1999 Nov 1;84(9):1049-54
pubmed: 10569662
J Card Fail. 2021 Nov;27(11):1285-1289
pubmed: 34280522
Circ Heart Fail. 2022 Jul;15(7):e008381
pubmed: 35766028
Eur Respir J. 2022 Feb 24;59(2):
pubmed: 34996829
ANZ J Surg. 2003 Sep;73(9):712-6
pubmed: 12956787
Am J Cardiol. 2019 Jul 1;124(1):122-130
pubmed: 31053293
Amyloid. 2018 Sep;25(3):167-173
pubmed: 30193539
Eur J Heart Fail. 2018 Jan;20(1):3-15
pubmed: 28925073